Profile
Mark G.
Eller worked as a Scientist at The Upjohn Co. He then worked as a Vice President-Clinical Pharmacology at Quintiles, Inc. (California) from 2001 to 2005.
After that, he worked as a SVP-Research & Clinical Development at Hoechst Marion Roussel, Inc. and as a Senior VP-Research & Clinical Development at Jazz Pharmaceuticals Plc.
Eller received his undergraduate and doctorate degrees from the University of Iowa.
Former positions of Mark G. Eller
| Companies | Position | End |
|---|---|---|
Quintiles, Inc. (California)
Quintiles, Inc. (California) Medical/Nursing ServicesHealth Services Provides therapeutic services | Chief Tech/Sci/R&D Officer | - |
The Upjohn Co.
The Upjohn Co. Pharmaceuticals: MajorHealth Technology Manufacturer of pharmaceuticals | Chief Tech/Sci/R&D Officer | - |
Hoechst Marion Roussel, Inc.
Hoechst Marion Roussel, Inc. Pharmaceuticals: GenericHealth Technology Develops, manufactures and sells generic pharmaceutical products | Chief Tech/Sci/R&D Officer | - |
| JAZZ PHARMACEUTICALS PLC | Corporate Officer/Principal | - |
Training of Mark G. Eller
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 5 |
|---|---|
The Upjohn Co.
The Upjohn Co. Pharmaceuticals: MajorHealth Technology Manufacturer of pharmaceuticals | Health Technology |
Quintiles, Inc. (California)
Quintiles, Inc. (California) Medical/Nursing ServicesHealth Services Provides therapeutic services | Health Services |
University of Iowa
University of Iowa Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Hoechst Marion Roussel, Inc.
Hoechst Marion Roussel, Inc. Pharmaceuticals: GenericHealth Technology Develops, manufactures and sells generic pharmaceutical products | Health Technology |
Jazz Pharmaceuticals Plc
Jazz Pharmaceuticals Plc Pharmaceuticals: MajorHealth Technology Engages in the development and commercialization of pharmaceutical products to treat neurological disorders | Health Technology |
- Stock Market
- Insiders
- Mark G. Eller
















